Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...

Over the past year, Eli Lilly ($LLY) stock has tumbled almost 24%, pressured by regulatory concerns, disappointing trial ...

Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...

Shares in Danish pharma company Novo Nordisk jumped after it halved the out-of-pocket price of Ozempic in the US and gained ...

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk's weight-loss treatment Wegovy gained U.S. approval to treat a progressive liver condition on Friday, as the Danish drugmaker looks to boost sales and widen insurance coverage. Eli ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...